Development of Entry-Targeted Oncolytic Measles Viruses

Michael D. Mühlebach, Roberto Cattaneo

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter describes the development of recombinant oncolytic measles viruses (MeV) that selectively enter and destroy tumor cells. The envelope of MeV is a favorable targeting substrate because receptor attachment and membrane fusion functions are separated on two proteins: the hemagglutinin (H) that binds receptors, and the fusion (F) protein that fuses the viral envelope with the cell membrane. The cell entry process, which depends on receptor recognition and occurs at the plasma membrane at neutral pH, results in the delivery of encapsidated genomes to the cytoplasm, where they replicate. Towards improving cancer specificity of oncolytic MeV, two types of cell entry targeting have been achieved. First, entry has been redirected through cancer-specific cell surface proteins. This was done by displaying specificity domains on H while also ablating binding to its natural receptors. Second, activation of the F protein was made dependent on secreted cancer proteases, while also interfering with F cleavage/activation by a ubiquitous intracellular protease. This chapter describes how entry-targeted MeV are produced: In short, gene cassettes with modified H or F coding regions are generated, and then introduced into the viral genome available on plasmid DNA. Such full-length genome plasmids are transfected in cell lines expressing, stably or transiently, the three viral proteins necessary for genome replication. Infectious centers form among these “rescue” cells, which allow isolation of clonal recombinant viruses. These are amplified, characterized in vitro, and then evaluated for their oncolytic activity in appropriate preclinical animal models.

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages51-75
Number of pages25
DOIs
StatePublished - Jan 1 2020

Publication series

NameMethods in Molecular Biology
Volume2058
ISSN (Print)1064-3745
ISSN (Electronic)1940-6029

Fingerprint

Oncolytic Viruses
Measles virus
Genome
Neoplasms
Plasmids
Peptide Hydrolases
Cell Membrane
Viral Envelope Proteins
Membrane Fusion
Viral Genome
Hemagglutinins
Viral Proteins
Membrane Proteins
Cytoplasm
Proteins
Animal Models
Viruses
Cell Line
DNA
Genes

Keywords

  • Entry targeting
  • Paramyxoviridae
  • Protease targeting
  • Receptor targeting
  • Recombinant measles virus
  • Rescue of Morbillivirus

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Mühlebach, M. D., & Cattaneo, R. (2020). Development of Entry-Targeted Oncolytic Measles Viruses. In Methods in Molecular Biology (pp. 51-75). (Methods in Molecular Biology; Vol. 2058). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-9794-7_4

Development of Entry-Targeted Oncolytic Measles Viruses. / Mühlebach, Michael D.; Cattaneo, Roberto.

Methods in Molecular Biology. Humana Press Inc., 2020. p. 51-75 (Methods in Molecular Biology; Vol. 2058).

Research output: Chapter in Book/Report/Conference proceedingChapter

Mühlebach, MD & Cattaneo, R 2020, Development of Entry-Targeted Oncolytic Measles Viruses. in Methods in Molecular Biology. Methods in Molecular Biology, vol. 2058, Humana Press Inc., pp. 51-75. https://doi.org/10.1007/978-1-4939-9794-7_4
Mühlebach MD, Cattaneo R. Development of Entry-Targeted Oncolytic Measles Viruses. In Methods in Molecular Biology. Humana Press Inc. 2020. p. 51-75. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-9794-7_4
Mühlebach, Michael D. ; Cattaneo, Roberto. / Development of Entry-Targeted Oncolytic Measles Viruses. Methods in Molecular Biology. Humana Press Inc., 2020. pp. 51-75 (Methods in Molecular Biology).
@inbook{ccc2db5b14614f219793dfc6bcfa0359,
title = "Development of Entry-Targeted Oncolytic Measles Viruses",
abstract = "This chapter describes the development of recombinant oncolytic measles viruses (MeV) that selectively enter and destroy tumor cells. The envelope of MeV is a favorable targeting substrate because receptor attachment and membrane fusion functions are separated on two proteins: the hemagglutinin (H) that binds receptors, and the fusion (F) protein that fuses the viral envelope with the cell membrane. The cell entry process, which depends on receptor recognition and occurs at the plasma membrane at neutral pH, results in the delivery of encapsidated genomes to the cytoplasm, where they replicate. Towards improving cancer specificity of oncolytic MeV, two types of cell entry targeting have been achieved. First, entry has been redirected through cancer-specific cell surface proteins. This was done by displaying specificity domains on H while also ablating binding to its natural receptors. Second, activation of the F protein was made dependent on secreted cancer proteases, while also interfering with F cleavage/activation by a ubiquitous intracellular protease. This chapter describes how entry-targeted MeV are produced: In short, gene cassettes with modified H or F coding regions are generated, and then introduced into the viral genome available on plasmid DNA. Such full-length genome plasmids are transfected in cell lines expressing, stably or transiently, the three viral proteins necessary for genome replication. Infectious centers form among these “rescue” cells, which allow isolation of clonal recombinant viruses. These are amplified, characterized in vitro, and then evaluated for their oncolytic activity in appropriate preclinical animal models.",
keywords = "Entry targeting, Paramyxoviridae, Protease targeting, Receptor targeting, Recombinant measles virus, Rescue of Morbillivirus",
author = "M{\"u}hlebach, {Michael D.} and Roberto Cattaneo",
year = "2020",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-9794-7_4",
language = "English (US)",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "51--75",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - Development of Entry-Targeted Oncolytic Measles Viruses

AU - Mühlebach, Michael D.

AU - Cattaneo, Roberto

PY - 2020/1/1

Y1 - 2020/1/1

N2 - This chapter describes the development of recombinant oncolytic measles viruses (MeV) that selectively enter and destroy tumor cells. The envelope of MeV is a favorable targeting substrate because receptor attachment and membrane fusion functions are separated on two proteins: the hemagglutinin (H) that binds receptors, and the fusion (F) protein that fuses the viral envelope with the cell membrane. The cell entry process, which depends on receptor recognition and occurs at the plasma membrane at neutral pH, results in the delivery of encapsidated genomes to the cytoplasm, where they replicate. Towards improving cancer specificity of oncolytic MeV, two types of cell entry targeting have been achieved. First, entry has been redirected through cancer-specific cell surface proteins. This was done by displaying specificity domains on H while also ablating binding to its natural receptors. Second, activation of the F protein was made dependent on secreted cancer proteases, while also interfering with F cleavage/activation by a ubiquitous intracellular protease. This chapter describes how entry-targeted MeV are produced: In short, gene cassettes with modified H or F coding regions are generated, and then introduced into the viral genome available on plasmid DNA. Such full-length genome plasmids are transfected in cell lines expressing, stably or transiently, the three viral proteins necessary for genome replication. Infectious centers form among these “rescue” cells, which allow isolation of clonal recombinant viruses. These are amplified, characterized in vitro, and then evaluated for their oncolytic activity in appropriate preclinical animal models.

AB - This chapter describes the development of recombinant oncolytic measles viruses (MeV) that selectively enter and destroy tumor cells. The envelope of MeV is a favorable targeting substrate because receptor attachment and membrane fusion functions are separated on two proteins: the hemagglutinin (H) that binds receptors, and the fusion (F) protein that fuses the viral envelope with the cell membrane. The cell entry process, which depends on receptor recognition and occurs at the plasma membrane at neutral pH, results in the delivery of encapsidated genomes to the cytoplasm, where they replicate. Towards improving cancer specificity of oncolytic MeV, two types of cell entry targeting have been achieved. First, entry has been redirected through cancer-specific cell surface proteins. This was done by displaying specificity domains on H while also ablating binding to its natural receptors. Second, activation of the F protein was made dependent on secreted cancer proteases, while also interfering with F cleavage/activation by a ubiquitous intracellular protease. This chapter describes how entry-targeted MeV are produced: In short, gene cassettes with modified H or F coding regions are generated, and then introduced into the viral genome available on plasmid DNA. Such full-length genome plasmids are transfected in cell lines expressing, stably or transiently, the three viral proteins necessary for genome replication. Infectious centers form among these “rescue” cells, which allow isolation of clonal recombinant viruses. These are amplified, characterized in vitro, and then evaluated for their oncolytic activity in appropriate preclinical animal models.

KW - Entry targeting

KW - Paramyxoviridae

KW - Protease targeting

KW - Receptor targeting

KW - Recombinant measles virus

KW - Rescue of Morbillivirus

UR - http://www.scopus.com/inward/record.url?scp=85071773468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071773468&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-9794-7_4

DO - 10.1007/978-1-4939-9794-7_4

M3 - Chapter

T3 - Methods in Molecular Biology

SP - 51

EP - 75

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -